Vis enkel innførsel

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: The relevance of time since last rituximab infusion and first experience from sporadic revaccinations

dc.contributor.authorKönig, Marton
dc.contributor.authorLorentzen, Åslaug Rudjord
dc.contributor.authorTorgauten, Hilde Marie
dc.contributor.authorTran, Trung
dc.contributor.authorSchikora-Rustad, Stine
dc.contributor.authorVaage, Eline Benno
dc.contributor.authorMygland, Åse Daasvand
dc.contributor.authorWergeland, Stig
dc.contributor.authorAarseth, Jan Harald
dc.contributor.authorAaberge, Ingeborg Sundsvalen
dc.contributor.authorTorkildsen, Øivind
dc.contributor.authorHolmøy, Trygve
dc.contributor.authorBerge, Tone
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorHarbo, Hanne-Cathrin Flinstad
dc.contributor.authorAndersen, Jan Terje
dc.contributor.authorMunthe, Ludvig Andre
dc.contributor.authorSøraas, Arne Vasli
dc.contributor.authorCelius, Elisabeth Gulowsen
dc.contributor.authorVaage, John T.
dc.contributor.authorLund-Johansen, Fridtjof
dc.contributor.authorNygaard, Gro Owren
dc.date.accessioned2022-06-28T08:32:23Z
dc.date.available2022-06-28T08:32:23Z
dc.date.created2021-12-13T13:05:46Z
dc.date.issued2021
dc.identifier.citationJournal of Neurology, Neurosurgery and Psychiatry. 2021, .en_US
dc.identifier.issn0022-3050
dc.identifier.urihttps://hdl.handle.net/11250/3001235
dc.description.abstractIntroduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective To characterise humoral immunity after mRNA-COVID-19 vaccination of people with multiple sclerosis (pwMS). Methods All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited to a national screening study. Humoral immunity was assessed by measuring antiSARS-CoV-2 SPIKE RBD IgG response 3–12 weeks after full vaccination, and compared with healthy subjects. Results 528 pwMS and 627 healthy subjects were included. Reduced humoral immunity (anti-SARS-CoV-2 IgGen_US
dc.language.isoengen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleHumoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: The relevance of time since last rituximab infusion and first experience from sporadic revaccinationsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1136/jnnp-2021-327612
dc.identifier.cristin1967772
dc.source.journalJournal of Neurology, Neurosurgery and Psychiatryen_US
dc.source.pagenumber4en_US


Tilhørende fil(er)

Thumbnail
Filnavn:
K%C3%B6nig_2021_Hum.pdf
Størrelse:
589.0Kb
Format:
PDF
Åpne
Thumbnail
Filnavn:
Humoral+immunity+to+SARS-CoV-2 ...
Størrelse:
576.8Kb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal